5-Aminolevulinic acid-based photodynamic therapy: Clinical research and future challenges

Cancer

Volumn 79, Issue 12, 1997, Pages 2282-2308

  Peng, Qian ^a,b   Warloe, Trond ^a   Berg, Kristian ^b   Moan, Johan ^b   Kongshaug, Magne ^b   Giercksky, Karl Erik ^a   Nesland, Jahn M ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

5 Aminolevulinic acid; Cancer; Diagnosis; Home synthesis; Light; Photodynamic therapy; Protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID; PHOTOSENSITIZING AGENT;

ARTICLE; BASAL CELL CARCINOMA; CLINICAL TRIAL; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG INDICATION; HEME SYNTHESIS; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PRURITUS; REGULATORY MECHANISM; SQUAMOUS CELL CARCINOMA; TOPICAL DRUG ADMINISTRATION; TREATMENT INDICATION; TREATMENT OUTCOME;

AMINOLEVULINIC ACID; FORECASTING; HEME; HUMANS; NEOPLASMS; PHOTOCHEMOTHERAPY; PROTOPORPHYRINS; RESEARCH; SKIN DISEASES; SKIN NEOPLASMS;

EID: 0030939781     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970615)79:12<2282::AID-CNCR2>3.0.CO;2-O     Document Type: Article

References (225)

1. Leibovici L, Schoenfeld N, Yehoshua HA, Mamet R, Rakowski E, Shindel A, et al. Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer. Cancer 1988;62:2297-300.
2. Schoenfeld N, Epstein O, Lahav M, Mamet R, Shaklai M, Atsmon A. The heme biosynthetic pathway in lymphocytes of patients with malignant lymphoproliferative disorders. Cancer Lett 1988;43:43-8.
3. Kondo M, Hirota N, Takaoka T, Kajiwara M. Heme-biosynthetic enzyme activities and porphyrin accumulation in normal liver and hepatoma cell line of rats. Cell Biol Toxicol 1993;9:95-105.
4. Rubino GF, Rasetti L. Porphyrin metabolism in human neoplastic tissues. Panminerva Med 1966;8:290-2.
5. Dailey HA, Smith A. Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase. Biochem J 1984;223:441-5.
6. Smith A. Mechanisms of toxicity of photoactivated artificial porphyrins: role of porphyrin-protein interactions. Ann N Y Acad Sci 1987;514:309-22.
7. El-Sharabasy MMH, El-Wassel AM, Hafez MM, Salim SA. Porphyrin metabolism in some malignant diseases. Br J Cancer 1992;65:409-12.
8. van Hillegersberg R, van den Berg JW, Kort WJ, Terpstra OT, Wilson JH. Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology 1992;103:647-51.
9. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principle and present clinical experience. J Photochem Photobiol B 1990;6:143-8.
10. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX: a clinical useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992;14:275-92.
11. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. J Am Acad Dermatol 1993;28:17-21.
12. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994;69:605-8.
13. Svanberg K, Andersson T, Killander D, Wang I, Stenram U, Ansersson-Engels S, et al. Photodynamic therapy of non-melanoma malignant tumors of the skin using topical δ-amino-levulinic acid sensitization and laser irradiation. Br J Dermatol 1994;130:743-51.
14. Warloe T, Peng Q, Heyerdahl H, Moan J, Steen HB, Giercksky KE. Photodynamic therapy with 5-aminolevulinic acid induced porphyrins and DMSO/EDTA for basal cell carcinoma. In: Cortese DA, editor. 5th International Photodynamic Association Biennial Meeting. Proc SPIE 1995;2371:226-35.
15. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolevulinic acid as an appropriate approach to the route treatment of superficial non-melanoma skin tumors. J Photochem Photobiol B 1995;29:53-7.
16. Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumors using 5 aminolaevulinic acid induced protoporphyrin IX: a pilot study. Gut 1995;36:67-75.
17. Fromm D, Kessel D, Webber J. Feasibility of photodynamic therapy using endogenous photosensitization for colon cancer. Arch Surg 1996;131:667-9.
18. Kriegmair M, Baumgartner R, Knuechel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996;155:105-10.
19. Huber RM, Gamarra F, Leberig A, Stepp H, Rick K, Baumgartner R. Inhaled 5-aminolevulinic acid (ALA) for photodynamic diagnosis and early detection of bronchial tumors: first experience in patients. In: Abstract book of 6th IPA meeting, 1996.
20. Goff BA, Bachor R, Kollias N, Hasan T. Effects of photodynamic therapy with topical application of 5-aminolevulinic acid on normal skin of hairless guinea pigs. J Photochem Photobiol B 1992;15:239-51.
21. Warloe T, Peng Q, Steen HB, Giercksky K-E. Localization of porphyrins in human basal cell carcinoma and normal skin tissue induced by topical application of 5-aminolevulinic acid. In: Spinelli P, Fante MD, Marchesini R. Photodynamic therapy and biomedical lasers. Amsterdam: Elsevier Science Publishers B. V., 1992:454-8.
22. Gaullier JM, Berg K, Peng Q, Anholt H, Selbo PK, Ma LM, et al. The use of esters of 5-aminolevulinic acid to improve photodynamic therapy on cells in culture. Cancer Res. 1997;57:1481-6.
23. Peng Q, Warloe T, Moan J, Heyerdahl H, Steen HB, Giercksky K-E, Nesland JM. ALA derivative-induced protoporphyrin IX build-up and distribution in human nodular basal cell carcinoma. Photochem Photobiol 1995;61:82S.
24. Peng Q, Moan J, Warloe T, Iani V, Steen HB, Bjørseth A, Nesland JM. Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B 1996:34:95-6.
25. Rebeiz CA, Reddy KN, Nandihalli UB, Velu J. Tetrapyrroledependent photodynamic herbicides. Photochem Photobiol 1990;52:1099-1117.
26. Wilson JHP, van Hillegersberg R, van den Berg JWO, Kort WJ, Terpstra OT. Photodynamic therapy for gastrointestinal tumors. Scand J Gastroenterol 1991;26(Suppl 188):20-5.
27. Lui H, Anderson RR. Photodynamic therapy in dermatology. Arch Dermatol 1992;128:1631-6.
28. Kennedy JC, Pross DC, Pottier RH. Photodynamic therapy of carcinoma using endogenous protoporphyrin IX induced by topical 5-aminolevulinic acid. In: Jung EG, Holick MF. Biologic effects of light. Berlin: Walter de Gruyter, 1993:372-86.
29. Batlle AM del C. Porphyrins, porphyrias, cancer and photodynamic therapy: a model for carcinogenesis. J Photochem Photobiol B 1993;20:5-22.
30. Bown SG. Photodynamic therapy in gastroenterology: current status and future prospects. Endoscopy 1993;25(Suppl):683-685.
31. van Hillegersberg R, Kort WJ, Wilson JHP. Current status of photodynamic therapy in oncology. Drugs 1994;48:510-27.
32. Roberts DJH, Cairnduff F. Photodynamic therapy of primary skin cancer: a review. Br J Plast Surg 1995;48:360-70.
33. Wolf P, Kerl H. Photodynamic therapy with 5-aminolevulinic acid: a promising concept for the treatment of cutaneous tumors. Dermatology 1995;190:183-5.
34. Stables GI, Ash DV. Antitumour treatment: photodynamic therapy. Cancer Treat Rev 1995;21:311-23.
35. Pottier RH, Kennedy CJ. Photodynamic therapy with 5-aminolevulinic acid: basic principles and application. Proc SPIE 1996;2625:2-10.
36. Nyamekye I. Vascular and other non-tumor application of photodynamic therapy. Lasers Med Sci 1996;11:3-10.
37. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 1997;65:235-251.
38. May BK, Bawden MJ. Control of heme biosynthesis in animals [review]. Semin Hematol 1989;26:150-6.
39. Scotto AW, Chang LF, Beattie DS. The characterization and submitochondrial localization of delta-aminolevulinic acid synthase and an associated amidase in rat liver mitochondria using an improved assay for both enzymes. J Biol Chem 1983;258:81-90.
40. Xu W, Kozak CA, Desnick RJ. Uroporphyrinogen-III synthase, molecular cloning, nucleotide sequence, expression of a mouse full-length cDNA, and its localization on mouse chromosome 7. Genomics 1995;26:556-62.
41. Elder GH., Evans JO. Evidence that the coproporphyrinogen oxidase activity of rat liver is situated in the intermembrane space of mitochondria. Biochem J 1978;172:345-7.
42. Grandchamp B, Phung N, Nordmann Y. The mitochondrial localization of coproporphyrinogen III oxidase. Biochem J 1978;176:97-102.
43. Ferreira GC, Andrew TL, Karr SW, Dailey HA. Organization of the terminal two enzymes of the heme biosynthetic pathway: orientation of protoporphyrinogen oxidase and evidence for a membrane complex. J Biol Chem 1988;263:3835-9.
44. Moore MR, McColl KEL, Rimigton C, Goldberg A. Disorders of porphyrin metabolism. New York: Plenum Press, 1987.
45. Bottomley SS, Muller-Eberhard U. Pathophysiology of heme synthesis [review]. Semin Hematol 1988;25:282-302.
46. Rossi E, Attwood PV, Garcia-Webb P, Costin KA. Inhibition of human lymphocyte ferrochelatase activity by hemin. Biochim Biophys Acta 1990;1038:375-81.
47. Wolfson SJ, Bartczak A, Bloomer JR. Effect of endogenous heme generation on delta-aminolevulinic acid synthase activity in rat liver mitochondria. J Biol Chem 1979;254:3543-6.
48. Hamilton JW, Bernent WI, Sinclair PR, Sinclair JF, Alcedo JA, Wetterhahn KE. Heme regulates hepatic 5-aminolevulinate synthase mRNA expression by decreasing mRNA half-life and not by altering its rate of transcription. Arch Biochem Biophys 1991;289:387-92.
49. Drew PD, Ades IZ. Regulation of the stability of chicken embryo liver delta-aminolevulinate synthase mRNA by hemin. Biochem Biophys Res Commun 1989;162:102-7.
50. Cable EE, Pepe JA, Karamitsios NC, Lambrecht RW, Bonkovsky HL. Differential effects of metalloporphyrins on messenger RNA levels of delta-aminolevulinate synthase and heme oxygenase: studies in cultured chick embryo liver cells. J Clin Invest 1994;94:649-54.
51. Yamamoto M, Kure S, Engel JD, Hiraga K. Structure, turnover, and heme-mediated suppression of the level of mRNA encoding rat liver delta-aminolevulinate synthase. J Biol Chem 1988;263:15973-9.
52. May BK, Dogra SC, Sadlon TJ, Bhasker CR, Cox TC, Bottomley SS. Molecular regulation of heme biosynthesis in higher vertebrates [review]. Prog Nucleic Acid Res Mol Biol 1995;51:1-51.
53. Borthwick IA, Srivastava G, Day AR, Pirola BA, Snoswell MA, May BK, et al. Complete nucleotide sequence of hepatic 5-aminolaevulinate synthase precursor. Eur J Biochem 1985;150:481-4.
54. Yamauchi K, Hayashi N, Kikuchi G. Translocation of delta-aminolevulinate synthase from the cytosol to the mitochondria and its regulation by hemin in the rat liver. J Biol Chem 1980;255:1746-51.
55. Hayashi N, Watanabe N, Kikuchi G. Inhibition by hemin of in vitro translocation of chicken liver delta-aminolevulinate synthase into mitochondria. Biochem Biophys Res Commun 1983;115:700-6.
56. Igarashi J, Hayashi N, Kikuchi G. Delta-aminolevulinate synthetases in the liver cytosol fraction and mitochondria of mice treated with allylisopropylacetamide and 3,5-dicarbethoxyl-1,4-dihydrocollidine. J Biochem (Tokyo) 1976;80:1091-9.
57. Berry JP. The role of lysosomes in the selective concentration of mineral elements: a microanalytical study. Cell Mol Biol 1996;42:395-411.
58. Lathrop JT, Timko MP. Regulation by heme of mitochondrial protein transport through a conserved amino acid motif. Science 1993;259:522-5.
59. Melefors O, Goossen B, Johansson HE, Stripecke R, Gray NK, Hentze MW. Translational control of 5-aminolevulinate synthase mRNA by iron-responsive elements in erythroid cells. J Biol Chem 1993;268:5974-8.
60. Peng Q, Warloe T, Moan J, Steen H, Giercksky KE, Nesland JM. Localization of ALA-induced porphyrins in normal and malignant tissues of mice, dogs and patients. Conference on photosensitization and photochemotherapy of cancer, Oslo, March 16-17, 1993. Abstract book, pp. S4.
61. Orenstein A, Kostenich G, Tsur H, Roitman L, Ehrenberg B, Malik Z. Photodynamic therapy of human skin tumors using topical application of 5-aminolevulinic acid, DMSO and EDTA. In: Brault D, Jori G, Moan J, Ehrenberg B. Photodynamic therapy of cancer II. Proc SPIE 1995;2325:100-5.
62. Morton CA, Whitehurst C, Moseley H, Moore JV, Mackie RM. Development of an alternative light source to lasers for photodynamic therapy. 1. Clinical evaluation in the treatment of pre-malignant non-melanoma skin cancer. Lasers Med Sci 1995;10:165-71.
63. Fritsch C, Verwohlt B, Bolsen K, Ruzicka T, Goerz G. Kinetics of erythrocyte and plasma porphyrins and excretion of delta-aminolevulinic acid, porphobilinogen and porphyrins in patients treated with topical delta-aminolevulinic acid photodynamic therapy. 6th IPA meeting, 1996. Abstract book.
64. Fijan S, Hönigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolevulinic acid and desferrioxamine. Br J Dermatol 1995;133:282-8.
65. Peng Q, Warloe T, Moan J, Heyerdahl H, Steen HB, Nesland JM, et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995;62:906-13.
66. Awadh N, Lam S. Photodetection and PDT for early lung cancer using aminolevulinic acid. 6th IPA meeting, 1996. Abstract book.
67. Scott JJ. The metabolism of δ-aminolevulinic acid. In: Wolstenholme GEW, Millar ECP. Ciba Foundation Symposium on Porphyrin Biosynthesis and Metabolism. London, J. and A. Churchill, Ltd, 1955:43-62.
68. Shimizu Y, Ida S, Naruto H, Urata G. Excretion of porphyrins in urine and bile after the administration of delta-aminolevulinic acid. J Lab Clin Med 1978;92:795-802.
69. 14C)-aminolevulinic acid in normal and porphyric human subjects, Clin Sci 1968;34:233-51.
70. Meyer US, Strand LJ, Doss M, Rees AC, Marver HS. Intermittent acute porphyria-demonstration of a genetic defect in porphobilinogen metabolism. N Engl J Med 1972;286:1277-82.
71. Mustajoki P, Timonen K, Gorchein A, Seppalainen AM, Matikainen E, Tenhunen R. Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer, no porphyric symptoms. Eur J Clin Invest 1992;22:407-11.
72. Gorchein A, Webber R. δ-Aminolevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin Sci 1987;72:103-12.
73. McGillion FB, Thompson GG, Moore MR, Goldberg A. The passage of δ-aminolevulinic acid across the blood-brain barrier of the rat. Biochem Pharmacol 1974;23:472-4.
74. Gabriel F, Juknat AA, del AM, Batlle C. Porphyrinogenesis in rat cerebellum: effect of high δ-aminolevulinic acid concentration. Gen Pharmac 1994;25:761-6.
75. Juknat AA, Kotler ML, del AM, Batlle C. High δ-aminolevulinic acid uptake in rat cerebral cortex: effect on porphyrin biosynthesis. Comp Biochem Physiol 1995;111C:143-150.
76. Mustajoki P, Koskelo P. Hereditary hepatic porphyrias in Finland. Acta Med Scand 1976;200:171-8.
77. Dagg JH, Goldberg A, Lochhead A, Smith JA. The relationship of lead poisoning to acute intermittent porphyria Q J Med 1965;34:163-75.
78. Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990;322:432-7.
79. Lofgren LA, Ronn AM, Nouri M, Lee CJ, Yoo D, Steinberg BM. Efficacy of intravenous δ-aminolevulinic acid photodynamic therapy on rabbit papillomas. Br J Cancer 1995;72:857-64.
80. Henderson BW, Vaughan L, Bellnier DA, van Leengoed H, Johnson PG, Oseroff AR. Photosensitization of murine tumor, vasculature and skin by using 5-aminolevulinic acid-induced porphyrin. Photochem Photobiol 1995;62:780-9.
81. Webber J, Kessel D, Fromm D. Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid. J Photochem Photobiol B 1997;37:151-3.
82. Egger NG, Motamedi M, Pow-Sang M, Orihuela E, Anderson KE. Accumulation of porphyrins in plasma and tissues of dogs after 6-aminolevulinic acid administration: implications for photodynamic therapy. Pharmacology 1996;52:362-70.
83. Pottier RH, Chow YFA, LaPlante JP, Truscott TG, Kennedy JC, Beiner LA. Non-invasive technique for obtaining fluorescence excitation and emission spectra in vivo. Photochem Photobiol 1986;44:679-87.
84. Peng Q, Moan J, Warloe T, Nesland JM, Rimington C. Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary carcinoma. Int J Cancer 1992;52:433-43.
85. Peng Q, Evensen JF, Rimington C, Moan J. A comparison of different photosensitizing dyes with respect to uptake by C3H-tumors and tissues of mice. Cancer Lett 1987;36:1-10.
86. 15N. Biochem J 1956;64:80-90.
87. Berlin NI, Neuberger A, Scott JJ. The metabolism of δ-aminolevulinic acid. 2. Normal pathway, studied with the aid of 14C. Biochem J 1956;64:90-100.
88. Jarrett A, Rimington C, Willoughby DA. 6-Aminolevulinic acid and porphyria. Lancet 1956;i:125-6.
89. Wooten RS, Smith KC, Ahlquist DA, Muller AA, Balm RK. Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative. Lasers Surg Med 1988;8:294-300.
90. Dougherty T, Cooper MT, Many TS. Cutaneous phototoxic occurrences in patients receiving Photofrin. Lasers Surg Med 1990;10:485-8.
91. Miller SJ. Biology of basal cell carcinoma. J Am Acad Dermatol 1991;24:161-75.
92. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649-62.
93. Giles GG, Marks R, Foley P. Incidence of non-melanocytic skin cancer treated in Australia. Br Med J 1088;296:13-7.
94. Davies DM. Malignant skin conditions. Br Med J 1984;290:1190-4.
95. Roenigk RK, Ratz JL, Bailin PL, Wheeland RG. Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol 1986;12:860-5.
96. Emmett AJ. Surgical analysis and biological behaviour of 2277 basal cell carcinomas. Aust N Z J Surg 1990;60:855-63.
97. Brady LW. External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys 1990;19:491-2.
98. Lovett RD, Perez CA, Shapiro SJ, Garcia DM. External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys 1990;19:235-42.
99. Dougherty TJ. Photosensitization of malignant tumors. Semin Surg Oncol 1986;2:24-37.
100. Berns MW, Wile AG. Hematoporphyrin phototherapy of cancer. Radiother Oncol 1986;7:233-40.
101. McCaughan JS. Overview of experiences with photodynamic therapy for malignancy in 192 patients. Photochem Photobiol 1987;46:903-9.
102. Dougherty TJ. Photosensitizers: therapy and detection of malignant tumors. Photochem Photobiol 1987;45:879-89.
103. Manyak MJ, Russo A, Smith PD, Glatstein E. Photodynamic therapy. J Clin Oncol 1988;6:380-91.
104. Dougherty TJ, Marcus SL. Photodynamic therapy. Eur J Cancer 1992;28A:1734-42.
105. Pass HI. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 1993;85:443-56.
106. Dougherty TJ. Photodynamic therapy. Photochem Photobiol 1993;58:895-900.
107. Fisher AMR, Murphree L, Gomer CJ. Clinical and preclinical photodynamic therapy. Lasers Surg Med 1995;17:2-31.
108. Schuitmaker JJ, Baas P, van Leengoed HLLM, van der Meulen FW, Star WM, van Zandwijk N. Photodynamic therapy: a promising new modality for the treatment of cancer. J Photochem Photobiol B 1996;34:3-12.
109. Sacchini V, Melloni E, Marchesini R, Luini A, Bandieramonte G, Spinelli P, et al. Preliminary clinical studies with PDT by topical TPPS administration in neoplastic skin lesions. Lasers Surg Med 1987;7:6-11.
110. Santoro O, Bandieramonte G, Melloni E, Marchesini R, Zunino F, Lepera P, Palo GD. Photodynamic therapy by topical meso-tetraphenylporphinesulfonate tetrasodium salt administration in superficial basal cell carcinoma. Cancer Res 1990;50:4501-3.
111. Wolf P, Kerl H. Photodynamic therapy in a patient with xeroderma pigmentosum. Lancet 1991;337:1613-4.
112. Gregory RO, Goldman L. Application of photodynamic ther-apy in plastic surgery. Lasers Surg Med 1986;6:62-6.
113. Orenstein A, Kostenich G, Tsur H, Kogan L, Malik Z. Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid application. Cancer Lett 1995;93:227-32.
114. Warloe T, Peng Q, Moan J, Qvist HL, Giercksky KE. Photochemotherapy of multiple basal cell carcinoma with endogenous porphyrins induced by topical application of 5-aminolevulinic acid. In: Spinelli P, Fante MD, Marchesini R. Photodynamic therapy and biomedical lasers. Amsterdam: Elsevier Science Publishers B.V., 1992:449-53.
115. Svanberg K, Andersson T, Killander D. Photodynamic therapy of human skin malignancies and laser-induced fluorescence diagnostics utilizing Photofrin and delta-aminolevulinic acid. In: Spinelli P, Fante MD, Marchesini R. Photodynamic therapy and biomedical lasers. Amsterdam: Elsevier Science Publishers B.V., 1992:436-40.
116. Lui H, Salasche S, Ariz T, Kollias N, Wimberly J, et al. Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical histologic study. Arch Dermatol 1995;131:737-8.
117. Oseroff AR, Babich D, Blaird-Wagner D, Hryhorenko E, Morgan I, Rittenhouse-Diakun K. ALA-PDT in dermatology: results and mechanisms. Photochem Photobiol 1996;63:89S.
118. Martin A, Tope WD, Grevelink JM, Starr JC, Fewkes JL, Flotte TJ, et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res 1995;287:665-74.
119. Szeimies R-M, Sassy T, Landthaler M. Penetration potency of topical applied δ-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Photochem Photobiol 1994;59:73-6.
120. Stoughton RB, Fritsch WC. Influence of dimethylsulfoxide (DMSO) on human percutaneous absorption. Arch Dermatol 1964;90:512-7.
121. Roberts DIH, Stables GI. Ash DV, Brown SB. Distribution of protoporphyrin IX in Bowen's disease and basal cell carcinomas treated with topical 5-aminolevulinic acid. Proc SPIE 1995;2371:490-4.
122. Tope WD, Kollias N, Ross EV, Martin A, Deutsch TF, Anderson RR. Oral delta-aminolevulinic acid for protoporphyrin IX fluorescence in basal cell carcinoma. 6th IPA meeting, 1996. Abstract book.
123. Karrer S, Szeimies R-M, Hohenleutner U, Heine A, Landthaler M. Unilateral localized basaliomatosis: treatment with topical photodynamic therapy after application of 5-amino-levulinic acid. Dermatology 1995;190:218-22.
124. Oseroff AR, Shanler SD, Buscaglia DA, van Leengoed E, Conti C, Somers K, et al. PDT with topical delta-aminolevulinic acid (ALA) for the treatment of patch and plaque stage cutaneous T-cell lymphoma. Lasers Surg Med 1995;7(Suppl):39.
125. Wolf P, Fink-Puches R, Cerroni L, Kerl H. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1994;31:678-80.
126. Ammann R, Hunziker T. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1995;33:541.
127. Malik Z, Ehrenberg B, Faraggi A. Inactivation of erythrocytic, lymphocytic and myelocytic leukemic cells by photoexcitation of endogenous porphyrins. J Photochem Photobiol B 1989;4:195-205.
128. Boehncke WH, Sterry W, Kaufmann R. Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet 1994;343:801.
129. Nelson JS, Jeffes EWB, Weinstein GD, McCullough JL. Topical 5-aminolevulinic acid (ALA) for the photodynamic therapy of psoriasis and actinic keratoses. Lasers Surg Med 1995;7(Suppl):43.
130. Stringer MR, Collins P, Robinson DJ, Stables GI, Sheehan-Dare RA. The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. J Invest Dermatol 1996;107:76-81.
131. Ammann R, Hunziker T, Braathen LR. Topical photodynamic therapy in verrucae. Dermatology 1995;191:346-7.
132. Frank RGJ, Bos JD, vd Meulen FW, Sterenborg HJCM. Photodynamic therapy for condylomata acuminata with local application of 5-aminolevulinic acid. Genitourin Med 1996;72:70-1.
133. Fehr MK, Chapman CF, Krasieva T, Tromberg BJ, McCullough JL, Berns MW, et al. Selective photosensitizer distribution in vulvar condyloma acuminatum after topical application of 5-aminolevulinic acid. Am J Obstet Gynecol 1996;174:951-7.
134. Divaris DXG, Kennedy JC, Pottier RH. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am J Pathol 1990;136:891-7.
135. Grossman M, Wimberly J, Dwyer P, Flotte T, Anderson RR. PDT for hirsutism. Lasers Surg Med 1995;7(Suppl):44.
136. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978;38:2628-35.
137. Dougherty TJ. Photoradiation therapy for cutaneous and subcutaneous malignancies. J Invest Dermatol 1981;77:122-4.
138. Kennedy J. HPD photoradiation therapy for cancer at Kingston and Hamilton. In: Kessel D, Dougherty TJ. Porphyrin photosensitization. New York: Plenum Press, 1983:53-62.
139. Tse DT, Kersten RC, Andersson RL. Hematoporphyrin derivative photoradiation therapy in managing nevoid basal cell carcinoma syndrome. Arch Ophthalmol 1984;102:990-4.
140. Tomio L, Calzavara F, Zorat PL, Corti L, Polico C, Reddi E, et al. Photoradiation therapy for cutaneous and subcutaneous malignant tumors using hematoporphyrin. In: Doiron DR, Gomer CJ. Porphyrin localization and treatment of tumor. New York: Alan R. Liss, Inc., 1984:829-40.
141. Cai WM, Yang Y, Zhang NW, Xie JG, Zhang X, Fan XJ, et al. Photodynamic therapy in the management of cancer: an analysis of 114 cases. Adv Exp Med Biol 1985;193:13-9.
142. Pennington DG, Waner M, Knox A. Photodynamic therapy for multiple skin cancers. Plast Reconst Surg 1987;82:1067-71.
143. Waldow SM, Lobraico RV, Kohler IK, Wallk S, Fritts HT. Photodynamic therapy for treatment of malignant cutaneous lesions. Lasers Surg Med 1987;7:451-6.
144. Wilson BD, Mang TS, Cooper M. Use of photodynamic therapy for treatment of extensive basal cell carcinomas. Facial Plast Surg 1989;6:185-9.
145. Buchanan RB, Carruth JAS, McKenzie AL, Williams SR. Photodynamic therapy in the treatment of malignant tumors of the skin and head and neck. Eur J Surg Oncol 1989;15:400-6.
146. Keller GS, Razum NI, Doiron DR. Photodynamic therapy for nonmelanoma skin cancer. Facial Plast Surg 1989;6:180-4.
147. McCaughan IS, Guy JT, Hicks W, Laufman L, Nims TA, J Walker. Photodynamic therapy for cutaneous and subcutaneous malignant neoplasms. Arch Surg 1989;124:211-6.
148. Feyh J, Goetz A, Muller W, Konigsberger R, Kastenbauer E. Photodynamic therapy in head and neck surgery. J Photochem Photobiol B 1990;7:353-8.
149. Wilson BD, Mang TS, Stoll H, Jones C, Cooper M, Dougherty TJ. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 1992;128:1597-601.
150. Hintschich C, Feyh J, Beyer-Machule C, Riedel K, Ludwig K. Photodynamic laser therapy of basal-cell carcinoma of the lid. Ger J Ophthalmol 1993;2:212-7.
151. Robinson PJ, Carruth JAS, Fairris GM. Photodynamic therapy: a better treatment for widespread Bowen's disease. Br J Dermatol 1988;119:59-61.
152. Jones CM, Mang T, Cooper M, Wilson BD, Stoll HL. Photodynamic therapy in the treatment of Bowen's disease. J Am Acad Dermatol 1992;27:979-82.
153. McCaughan JS. Photoradiation of malignant tumors photosensitized with hematoporphyrin derivative. In: Doiron DR, Gomer CJ. Porphyrin localization and treatment of tumor. New York: Alan R. Liss, Inc., 1984:805-27.
154. Bandieramonte G, Marchesini R, Melloni E, Andreoli C, di Pietro S, Spinelli P, et al. Laser phototherapy following HpD administration in superficial neoplastic lesions. Tumor 1984;70:327-34.
155. Petrelli NJ, Cebollero JA, Rodriguez-Bigas M, Mang T. Photodynamic therapy in the management of neoplasms of the perianal skin. Arch Surg 1992;127:1436-8.
156. Dilkes MG, Dejode ML, Gardiner Q, Kenyon GS, McKelvie P. Treatment of head and neck cancer with photodynamic therapy: results after one year. J Laryngol Otol 1995;109:1072-6.
157. Wolf P, Fink-Puches R, Reimann-Weber A, Kerl H. Site and surface fluorescence-dependent response of solar keratoses to topical 5-aminolevulinic acid photodynamic therapy (ALA-PDT) by UVA and/or different wavebands of visible light. Photochem Photobiol 1996;63:22S.
158. Szeimies R-M, Karrer S, Sauerwald A, Landthaler M. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 1996;192:246-51.
159. Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989;15:315-28.
160. Levy IG, Waterfield E, Richter A, Smits C, Lui H, Hruza L, et al Photodynamic therapy of malignancies with bezoporphyrin derivative monoacid ring A. Proc SPIE 1994;2078:91-101.
161. Levy JG, Chan A, Strong HA. The clinical status of bezoporphyrin derivative. Proc SPIE 1996;2625:81-95.
162. Doiron DR, Razum NJ, Snyder AB, Crean DH. Clinical update of SnET2. Photochem Photobiol 1996;63:5S.
163. Allen RP, Kessel D, Tharratt RS, Volz V. Photodynamic therapy of superficial malignancies with NPe6 in man. In: Spinelli P, Fante MD, Marchesini R. Photodynamic therapy and biomedical lasers. Amsterdam: Elsevier Science Publishers B.V., 1992:441-5.
164. Wieman TJ, Taber SW, Fingar VH. Photodynamic therapy using NPe6 for the treatment of cutaneous disease. Photochem Photobiol 1995;61(Suppl):51S.
165. Grant WE, Hopper C, MacRobert AJ, Speight PM, Bown SG. Photodynamic therapy of oral cancer: photosensitization with systemic aminolevulinic acid. Lancet 1993;342:147-8.
166. Loh CS, MacRobert AJ, Regula J, Bown SG. Oral vs. i.v. administration of 5-ALA. Br J Cancer 1993;68:41-51.
167. Mlkvy P, Messmann H, Regula J, Conio M, Pauer M, Millson CE, et al. Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5-aminolevulinic acid (ALA) induced protoporphyrin DC (PPIX): a pilot study. Neoplasma 1995;42:109-13.
168. Fan K, Hopper C, Speight P, Buonaccorsi G, MacRobert A, Bown S. Photodynamic therapy with ALA sensitisation for dysplastic and microinvasive carcinoma of the mouth. Lasers Surg Med 1995;7(Suppl):40.
169. Mlkvy P, Messmann H, Debinski H, Regula J, Conio M, et al. Photodynamic therapy for polyps in familial adenomatous polyposis: a pilot study. Eur J Cancer 1995;31A:1160-5.
170. Warloe T, Peng Q, Heyerdahl H, Wæhre H, Moan J, Steen H, Giercksky K-E. Photodynamic therapy of human tubulovillous adenomas. Proc SPIE 1995;2325:425-36.
171. Gossner L, Sroka R, Hahn EG, Ell C. Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid. Gastrointest Endosc 1995;41:55-7.
172. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994;44:836-41.
173. Steinbach P, Kriegmair M, Baumgartner R, Hofstadter F, Knuechel R. Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells. Urology 1994;44:676-81.
174. Kriegmair M, Stepp H, Steinbach P, Lumper W, Ehsan A, Stepp HG, et al. Fluorescence cystoscopy following intravesical instillation of 5-aminolevulinic acid: a new procedure with high sensitivity for detection of hardly visible urothelial neoplasias. Urol Int 1995;55:190-96.
175. Jichlinski P, Leisinger HJ, Forrer M, Mizeret J, Glanzmann T, Wagnieres G, et al. Clinical evaluation of a screening method of bladder transitional cell carcinoma by induced fluorescence of protoporphyrin IX with topical application of delta-aminolevulinic acid: preliminary results. Lasers Surg Med 1995;7(Suppl):42.
176. Kriegmair M, Baumgartner R, Lumper W, Waidelich R, Hofstetter A. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol 1996;77:667-71.
177. Leveckis J, Burn JL, Brown NJ, Reed MWR. Kinetics of endogenous protoporphyrin DC induction by aminolevulinic acid: preliminary studies in the bladder. J Urol 1994;152:550-3.
178. Iinuma S, Bachor R, Flotte T, Hasan T. Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIK in an orthotopic rat bladder tumor model. J Urol 1995;153:802-6.
179. van Staveren HJ, Beek JF, Verlaan CWJ, Edixhoven A, Saarnak AE, et al. Whole bladder wall photodynamic therapy using 5-ALA: an experimental study in pigs. Proc SPIE 1996;2625:70-6.
180. Chang SC, MacRobert AJ, Bown SG. Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5-aminolevulinic acid. J Urol 1996;155:1744-8.
181. Chang SC, MacRobert AJ, Bown SG. Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: light diffusion and histological changes. J Urol 1996;155:1749-53.
182. Marcus SL, Dugan MH. Global status of clinical photodynamic therapy: the registration process for a new therapy. Lasers Surg Med 1992;12:318-24.
183. Baumgartner R, Kriegmair M, Jocham D, Hofstetter A, Huber R, Karg O, et al. Photodynamic diagnosis (PDD) of early stage malignancies: preliminary results in urology and pneumology. Proc SPIE 1992;1641:107-12.
184. Baumgartner R, Fuchs N, Jocham D, Stepp H, Unsöld E. Pharmacokinetics of fluorescent polyporphyrin Photofrin II in normal rat tissue
185. Kriegmair M, Baumgartner R, Lumper W, Riesenberg R, Stocker S, Hofstetter A. Fluorescence cystoscopy following intravesical instillation of aminolevulinic acid (ALA). J Urol 1993;149(Suppl):240A.
186. Baumgartner R, Huber RM, Haubinger K, Gamarra F, Stepp H, Rick K, et al. Inhalation of 5-ALA: a new technique for fluorescence detection of neoplasias in the lung. An International Symposium on Biomedical Optics, San Jose, CA, February 4-10, 1995. Technical Abstract, 126.
187. Stummer W, Stepp H, Stocker S, Baumgartner R. Intra-operative fluorescence detection of human malignant glioma by 5-ALA induced protoporphyrin: first clinical experience. 6th IPA meeting, 1996. Abstract book.
188. Stringer MR. Problems associated with the use of broadband illumination sources for photodynamic therapy. Phys Med Biol 1995;40:1733-5.
189. Waldow SM, Dougherty TJ. Interaction of hyperthermia and photoradiation therapy. Radiat Res 1984;97:380-5.
190. Kimel S, Svaasand LO, Hammer-Wilson M, Gottfried V, Cheng S, Svaasand E, et al. Demonstration of synergistic effects of hyperthemia and photodynamic therapy using the chick chorioallantoic membrane model. Lasers Surg Med 1992;12:432-40.
191. Hisazumi H, Naito K, Misakii T, Koshida K, Yamamoto H. An experimental study of photodynamic therapy using a pulsed gold vapor laser. In: Iori G, Perria C. Photodynamic therapy of tumors and other diseases. Padova: Libreria Progetto Editore, 1985:252-4.
192. Cowed PA, Grace JR, Forbes IJ. Comparison of the efficacy of pulsed and continuous-wave red laser light in induction of photocytotoxicity by hematoporphyrin derivative. Photochem Photobiol 1984;39:115-7.
193. Barr H, Boules PB, MacRobert AJ, Tralau CJ, Phillips D, Bown SG, et al. Comparison of lasers for photodynamic therapy with a phthalocyanine photosensitizer. Lasers Med Sci 1989;4:7-12.
194. Moan J, Sommer S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. Cancer Res 1985;45:1608-10.
195. Moan J, Iani V, Ma LW. Choice of the proper wavelength for photochemotherapy. Proc SPIE 1996;2625:544-9.
196. Szeimies RM, Abels C, Fritsch C, Karrer S, Steinbach P, Baumler W, et al. Wavelength dependency of photodynamic effects after sensitization with 5-aminolevulinic acid in vitro and in vivo. J Invest Dermatol 1995;105:672-7.
197. Moan J, Berg K, Iani V. Action spectra of dyes relevant for photodynamic therapy. In: Moser JG. Quantitative data of 2nd and 3rd generation photosensitizers for photodynamic therapy. London: Harwood Academic Publishers. In press.
198. Schneckenburger H, König K, Kunzi-Rapp K, Westphal-Frösch C, Rück A. Time-resolved in-vivo fluorescence of photosensitizing porphyrins. J Photochem Photobiol B 1993;21:143-7.
199. Moan J, Iani V, Ma LW, Peng Q. Photodegradation of sensitizers in mouse skin during PCT. Proc SPIE 1996;2625:187-92.
200. Moan J, Høydalsvik E, Peng Q, Ma LW, Warloe T, Heyerdahl H. Measurements of sensitizer fluorescence in patients by means of an ordinary fluorescence spectrometer. Proc SPIE 1995;2371:516-9.
201. Streckyte G, Berg K, Moan J. Photomodification of ALA-induced protoporphyrin IX in cells in vitro. Proc SPIE 1995;2325:58-65.
202. König K, Meyer H, Schneckenburger H, Rück A. The study of endogenous porphyrins in human skin and their potential for photodynamic therapy by laser induced fluorescence spectroscopy. Lasers Med Sci 1993;8:127-32.
203. Inhoffen HH, Brockmann H, Bliesener KM. Photoprotoporphyrine und ihre Umwandlung in Spirographissowie Isospirographis-porphyrin. Liebigs. Ann Chem 1969;730:173-85.
204. Cox GS, Krieg M, Whitten MG. Self-sensitized photo-oxidation of protoporphyrin DC derivatives in aqueous surfactant solutions: product and mechanistic studies. J Am Chem Soc 1982;104:6930-7.
205. Cox GS, Bobillier C, Whitten DG. Photo-oxidation and singlet oxygen sensitization by protoporphyrin IX and its photo-oxidation products. Photochem Photobiol 1982;36:401-7.
206. Krieg M, Whitten MG. Self-sensitized photooxidation of protoporphyrin IX and related free-base porphyrins in natural and model membrane systems: evidence for novel photooxidation pathways involving amino acids. J Am Chem Soc 1984;106:2479-81.
207. Cox GS, Whitten DG. Environmental effects on photochemical reactions: contrasts in the photo-oxidation behavior of protoporphyrin IX in solution, monolayer films, organized monolayer assemblies, and micelles. J Am Chem Soc 1987;100:1293-5.
208. Gudgin EF, Pottier RH. On the role of protoporphyrin IX photoproducts in photodynamic therapy. J Photochem Photobiol B 1995;29:91-3.
209. Charlesworth P, Truscott TG. The use of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT). J Photochem Photobiol B 1993;18:99-100.
210. König K, Schneckenburger H, Rück A, Steiner R. In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins. J Photochem Photobiol B 1993;18:287-90.
211. Ahram M, Cheong WF, Ward K, Kessel D. Photoproduct formation during irradiation of tissues containing protoporphyrin. J Photochem Photobiol B 1994;26:203-4.
212. Warloe T. Photodynamic therapy of human malignant tumors [Ph.D dissertation]. The University of Oslo, 1995.
213. Heyerdahl H, Warloe T, Peng Q, Svanberg K, Moan J, Steen H, et al. Dosimetry and light distribution systems for photodynamic therapy at the Norwegian Radium Hospital. Proc SPIE 1994;2078:27-36.
214. Kloek J, van Henegouwen GMJB. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol 1996;64:994-1000.
215. Peng Q, Moan J. Correlation of distribution of sulphonated aluminum phthalocyanines with their photodynamic effect in tumour and skin of mice bearing CaD2 mammary carcinoma. Br J Cancer 1995;72:565-74.
216. Peng Q, Moan J, Ma LW, Nesland JM. Uptake, localization and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma. Cancer Res 1995;55:2620-6.
217. Hua Z, Gibson SL, Foster TH, Hilf R. Effectiveness of delta-aminolevulinic acid-induced protoporphyrin as a photosensitizer for photodynamic therapy in vivo. Cancer Res 1995;55:1723-31.
218. Regula J, Ravi B, Bedwell J, MacRobert AJ, Bown SG. Photodynamic therapy using 5-aminolevulinic acid for experimental pancreatic cancer-prolonged animal survival. Br J Cancer 1994;70:248-54.
219. Fukuda H, Paredes S, Batlle AMC. Tumor-localizing properties of porphyrins: in vivo studies using free and liposome encapsulated aminolevulinic acid. Comp Biochem Physiol 1992;102B:433-6.
220. Heyerdahl H, Wang I, Liu DL, Berg R, Andersson-Engels S, Peng Q, et al. Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumors and normal tissues. Cancer Lett 1997;112:225-31.
221. Svanberg K, Clemente LP, Clemente MP, Wang I, Warloe T, Andersson-Engels S, et al. Pharmacokinetic studies of δ-aminolevulinic acid-induced protoporphyrin IX build-up in some malignant tumours. Proc SPIE 1995;2387:30-42.
222. Goldstein SR, Bonner RF, Grantham FH, Gullino P, Dedrick RLA. Fiber optic micro-fluorimeter for acute and chronic in vivo studies. In: Eberhart RC. Advances in bioengineering. New York: American Society of Mechanical Engineers, 1978:103-5.
223. Frisoli JK, Tudor EG, Flotte TJ, Hasan T, Deutsch TF, Schomacker KT. Pharmacokinetics of a fluorescent drug using laser-induced fluorescence. Cancer Res 1993;53:5954-61.
224. Loh CS, Vernon D, MacRobert AJ, Bedwell J, Bown SG, Brown SB. Endogenous porphyrin distribution induced by 5-aminolevulinic acid in the tissue layers of the gastrointestinal tract. J Photochem Photobiol B 1993;20:47-54.
225. Rittenhouse-Diakun K, van Leengoed H, Morgan J, Hryhorenko E, Paszkiewicz G, Whitaker JE, et al. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor δ-aminolevulinic acid (ALA). Photochem Photobiol 1995;61:523-8.